Particulars (Rs. in cr) | Q2FY25 | Q2FY24 | YoY (%) | Q1FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 183.00 | 139.00 | 32.00% | 156.00 | 17.00% |
EBITDA | 76.00 | 57.00 | 32.00% | 61.00 | 24.00% |
EBITDA Margin (%) | 41.50% | 41.30% | 22 bps | 39.20% | 234 bps |
PAT | 42.00 | 34.00 | 26.00% | 32.00 | 34.00% |
EPS (Rs.) | 4.08 | 3.25 | 26.00% | 3.05 | 34.00% |
Source: Company Filings; stockaxis Research
Q2FY25 Result Highlights
Vijaya Diagnostics Centre Ltd. delivered another impressive quarter with strong
growth across its key metrics. Consolidate revenue from operations grew 32% YoY,
primarily driven by volume growth of 30% YoY and footfall growth of 24% YoY, with
contributions coming from both the existing and newly launched centres. Gross margins
saw a decline of 80 bps YoY and 56 bps QoQ, due to elevated raw material costs that
rose 40% YoY and 23% QoQ. Consolidated EBITDA came in at 76cr, up 32% YoY and 24%
QoQ, mainly driven by higher revenue growth. Consequently, the EBITDA margins expanded
by 22 bps YoY and 234 bps QoQ. Profit after tax stood at 42.14cr, up 26% YoY and
34% QoQ, (Q2FY24: 33.57cr, Q1FY25: 31.51cr).
Vijaya Diagnostic Centre Limited (VDCL) reported a strong operational performance in Q2 FY25. The growth was primarily volume driven, with contributions coming both from existing and newly launched centres, which are breaking even more quickly while maintaining a strong B2C shift. On the operational front:
Segment Performance
Guidance:
i) Capex: Guidance to open 10 new hub centres in FY25 and
FY26, with an estimated capex outlay of Rs 200cr (40cr was spent in
H1FY25), (ii) Management targets 15-16% growth while maintaining 40% EBITDA margins,
(iii) Test per footfall should stay in the range of 3.4-3.5 going forward, (iv)
The mix of wellness should remain in the same 13-14% range.
PH Pune revenue:
Q2FY25 revenues stood at Rs. 12.2cr, with 40% EBITDA margins.
Wellness Revenues
Q2FY25 revenues 22.5cr
Flagship centres
The flagship centres generate about per 60cr of revenue per year (~5cr month). This
is less than 10% of the consolidated revenues of the company.
Capex
Near-term challenges
Technological Initiatives
Debt
Medinova Diagnostic services integration
Future Strategies
Other Key Points
Break Even
Vijaya Diagnostic Centre reported strong earnings growth in Q2FY25. Vijaya’s integrated model providing both radiology and pathology coupled with high B2C mix and adoption of the latest confidence instills greater confidence in its growth potential. Its confidence to grow in double digits in its core Hyderabad market is comforting while its expansion in high growth potential geographies such as Pune and Kolkata should accelerate its growth. We believe it is poised to win in new markets given strong B/S, integrated play, high B2C mix and latest technologies. Moreover, receding pricing pressures bodes well for the overall sector.
Considering improving growth visibility, expansion in fast growing geographies, management’s execution track record, receding pricing pressures, the confidence of double-digit volume growth, high brand recall, robust technical capabilities, and leading position in India’s high growth diagnostics market, the stock is poised for rerating. At a CMP of Rs.1040, the stock is trading at 48x FY26E EV/EBITDA. We maintain HOLD rating on the stock.
Particulars (Rs. in cr) | Q2FY25 | Q2FY24 | YoY (%) | Q1FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 183.00 | 139.00 | 32.00% | 156.00 | 17.00% |
Cost of raw materials consumed | 23.00 | 16.00 | 41.00% | 19.00 | 23.00% |
Gross Profit | 160.00 | 123.00 | 31.00% | 137.00 | 16.00% |
Gross Margin (%) | 87.43% | 88.23% | (80) bps | 88.00% | (56) bps |
Employee Benefit expense | 28.00 | 22.00 | 28.00% | 27.00 | 2.00% |
Other expenses | 56.00 | 43.00 | 30.00% | 49.00 | 15.00% |
EBITDA | 76.00 | 57.00 | 32.00% | 61.00 | 24.00% |
EBITDA Margin (%) | 41.50% | 41.30% | 22 bps | 39.20% | 234 bps |
Depreciation and amortisation expenses | 17.00 | 14.00 | 23.00% | 17.00 | 1.00% |
EBIT | 59.00 | 44.00 | 35.00% | 45.00 | 33.00% |
Finance cost | 6.00 | 6.00 | 11.00% | 6.00 | 3.00% |
Other Income | 5.00 | 7.00 | -33.00% | 4.00 | 27.00% |
PBT | 57.00 | 45.00 | 28.00% | 42.00 | 37.00% |
Tax expenses | 15.00 | 11.00 | 37.00% | 10.00 | 45.00% |
PAT | 42.00 | 34.00 | 26.00% | 32.00 | 34.00% |
EPS (Rs.) | 4.08 | 3.25 | 26.00% | 3.05 | 34.00% |